SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Of note, empagliflozin can also bind to SGLT-1, albeit with a lower affinity than SGLT-2; strengthening the suggestion that empagliflozin could act, among others, through SGLT-1, dual SGLT-1/SGLT-2 inhibitor phlorizin recently found to ameliorate NAFLD in Type 2 diabetic mice [68].